Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors

NCT05060276 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Protocol changed to Phase 2

Conditions

Relapsed Solid Neoplasm
Refractory Cancer
Solid Tumor, Adult

Interventions

BIOLOGICAL: STI-3258

Sponsor

Sorrento Therapeutics, Inc.